363 569

Cited 31 times in

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

DC Field Value Language
dc.contributor.author백순명-
dc.date.accessioned2019-09-20T07:22:38Z-
dc.date.available2019-09-20T07:22:38Z-
dc.date.issued2018-
dc.identifier.issn0167-6806-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170856-
dc.description.abstractBACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients. Tamoxifen for 5 years was also given to patients > 50 years and those < 50 years with ER+ and/or progesterone receptor-positive (PR+) tumors. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Median follow-up time was 11.2 years. RESULTS: In univariate analyses, RS was a significant predictor of outcome. In multivariate analyses, RS remained a significant independent predictor of outcome beyond clinico-pathologic factors, age, and type of surgery (p < 0.001). In the study population (n = 1065), the disease-free survival (DFS) hazard ratio (HR) with adding P to AC was 0.87 (95% CI 0.72-1.05; p = 0.14). RS was not a significant predictor of P benefit: for DFS, HRs for adding P to AC in RS low, intermediate, and high subgroups were 1.01 (95% CI 0.69-1.47; p = 0.99), 0.84 (95% CI 0.62-1.14; p = 0.26), and 0.81 (95% CI 0.60-1.10; p = 0.21), respectively (interaction p = 0.64). Similar findings were observed for the other study endpoints. CONCLUSIONS: RS maintains significant prognostic impact in ER-positive, node-positive patients treated with adjuvant chemotherapy plus tamoxifen. However, RS did not significantly predict benefit from adding paclitaxel to AC chemotherapy. (Trial Registration: PDQ: NSABP-B-28).-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKluwer Academic-
dc.relation.isPartOfBreast Cancer Research and Treatment-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentBioMedical Science Institute (의생명과학부)-
dc.contributor.googleauthorEleftherios P. Mamounas-
dc.contributor.googleauthorGong Tang-
dc.contributor.googleauthorSoonmyung Paik-
dc.contributor.googleauthorFrederick L. Baehner-
dc.contributor.googleauthorQing Liu-
dc.contributor.googleauthorJong-Hyeon Jeong-
dc.contributor.googleauthorSeong-Rim Kim-
dc.contributor.googleauthorSteven M. Butler-
dc.contributor.googleauthorFarid Jamshidian-
dc.contributor.googleauthorDiana B. Cherbavaz-
dc.contributor.googleauthorAmy P. Sing-
dc.contributor.googleauthorSteven Shak-
dc.contributor.googleauthorThomas B. Julian-
dc.contributor.googleauthorBarry C. Lembersky-
dc.contributor.googleauthorD. Lawrence Wickerham-
dc.contributor.googleauthorJoseph P. Costantino-
dc.contributor.googleauthorNorman Wolmark-
dc.identifier.doi10.1007/s10549-017-4550-8-
dc.contributor.localIdA01823-
dc.relation.journalcodeJ00403-
dc.identifier.eissn1573-7217-
dc.identifier.pmid29128898-
dc.subject.keywordBreast cancer-
dc.subject.keywordNode-positive-
dc.subject.keywordPrognosis and prediction-
dc.subject.keywordRecurrence score-
dc.contributor.alternativeNamePaik, Soon Myung-
dc.contributor.affiliatedAuthor백순명-
dc.citation.volume168-
dc.citation.number1-
dc.citation.startPage69-
dc.citation.endPage77-
dc.identifier.bibliographicCitationBreast Cancer Research and Treatment, Vol.168(1) : 69-77, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.